Page last updated: 2024-12-07

amarogentin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Amarogentin is a secoiridoid glycoside found in various plants of the Gentianaceae family. It exhibits a wide range of biological activities, including anti-inflammatory, antioxidant, antidiabetic, and neuroprotective effects. Its complex structure and potent bioactivity have sparked significant interest in its potential as a therapeutic agent. Research into amarogentin has focused on elucidating its mechanisms of action, exploring its potential applications in medicine, and developing efficient methods for its extraction and synthesis.'
```

amarogentin: secoiridoid glycoside [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

amarogentin : A secoiridoid glycoside that consists of (4aS,5R,6R)-5-ethenyl-6-hydroxy-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-1-one having a 2-O-[(3,3',5-trihydroxybiphenyl-2-yl)carbonyl]-beta-D-glucopyranosyl group attached at position 6 via a glycosidic linkage. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID115149
CHEBI ID2622
SCHEMBL ID1031187
MeSH IDM0268568

Synonyms (24)

Synonym
sweroside-2'-(3'',5'',3'''-trihydroxydiphenyl)-2''-carboxylic acid ester
(4as,5r,6s)-5-ethenyl-1-oxo-4,4a,5,6-tetrahydro-1h,3h-pyrano[3,4-c]pyran-6-yl- 2-o-[(3,3',5-trihydroxybiphenyl-2-yl)carbonyl]-beta-d-glucopyranoside
CHEBI:2622
(4ar)-5t-ethenyl-6c-[o(2)-(3,5,3'-trihydroxybiphenyl-2-ylcarbonyl)-beta-d-glucopyranosyloxy]-4,4ar,5,6-tetrahydro-3h-pyrano[3,4-c]pyran-1-one
21018-84-8
amarogentin
C09767 ,
[(2s,3r,4s,5s,6r)-2-[[(3s,4r,4as)-4-ethenyl-8-oxo-4,4a,5,6-tetrahydro-3h-pyrano[3,4-c]pyran-3-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl] 2,4-dihydroxy-6-(3-hydroxyphenyl)benzoate
1h,3h-pyrano(3,4-c)pyran-1-one, 5-ethenyl-4,4a,5,6-tetrahydro-6-((2-o-((3,3',5-trihydroxy(1,1'-biphenyl)-2-yl)carbonyl)-beta-d-glucopyranosyl)oxy)-, (4as,5r,6s)-
unii-5l82gt5i0w
2-(4as-(4aalpha,5beta,6alpha))-3,3',5-trihydroxy-(1,1'-biphenyl)-2-carboxylate
(1,1'-biphenyl)-2-carboxylic acid, 3,3',5-trihydroxy-, 2-ester with 5-ethenyl-6-(beta-d-glucopyranosyloxy)-4,4a,5,6-tetrahydro-1h,3h-pyrano(3,4-c)pyran-1-one, (4as-(4aalpha,5beta,6alpha))-
5l82gt5i0w ,
S1273
AKOS015896722
amarogentin [mi]
SCHEMBL1031187
DBOVHQOUSDWAPQ-WTONXPSSSA-N
Q3613679
(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-(((3s,4r,4as)-8-oxo-4-vinyl-3,4,4a,5,6,8-hexahydropyrano[3,4-c]pyran-3-yl)oxy)tetrahydro-2h-pyran-3-yl 3,3',5-trihydroxy-[1,1'-biphenyl]-2-carboxylate
CS-0022673
HY-N2447
DTXSID501029787
gtpl12459

Research Excerpts

Overview

Amarogentin (AMA) is a secoiridoid glycoside extracted from Swertia and Gentiana roots. It exhibits many biological effects such as antioxidative, anti-inflammatory, and antitumor activities.

ExcerptReferenceRelevance
"Amarogentin (AMA) is a secoiridoid glycoside extracted from Swertia and Gentiana roots and exhibits many biological effects such as antioxidative, anti-inflammatory, and antitumor activities. "( Anti-inflammatory effects of amarogentin on 2,4-dinitrochlorobenzene-induced atopic dermatitis-like mice and in HaCat cells.
Chen, S; Li, F; Lyu, Y; Ran, C; Wang, H; Wang, L; Xing, S; Yao, Y; Zhang, Q, 2023
)
2.64
"Amarogentin is an efficacious Chinese herbal medicine and a component of the bitter apricot kernel. "( Chinese Medicine Amygdalin and β-Glucosidase Combined with Antibody Enzymatic Prodrug System As A Feasible Antitumor Therapy.
Li, QX; Li, YL; Liu, RJ; Shen, XQ, 2018
)
1.92
"Amarogentin is a bitter-tasting secoiridoid glycoside isolated from an herb. "( Amarogentin ameliorates diabetic disorders in animal models.
Chao, PC; Cheng, JT; Ku, PM; Lee, KS; Niu, CS; Niu, HS, 2016
)
3.32
"Amarogentin is a potent inhibitor of type I DNA topoisomerase from Leishmania and exerts its effect by interaction with the enzyme, preventing binary complex formation."( Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovani.
Chakravarty, AK; Cordell, GA; Gil, RR; Majumder, HK; Mukhopadhyay, S; Ray, S, 1996
)
2.46

Effects

ExcerptReferenceRelevance
"Amarogentin has been reported to have a preventive effect on liver cancer via inducing cancer cell apoptosis. "( Amarogentin Induces Apoptosis of Liver Cancer Cells via Upregulation of p53 and Downregulation of Human Telomerase Reverse Transcriptase in Mice.
Gong, J; Huang, C; Li, R; Zhang, Y, 2017
)
3.34

Treatment

ExcerptReferenceRelevance
"Amarogentin treatment (15~60  μM) inhibited platelet aggregation induced by collagen, but not thrombin, arachidonic acid, and U46619."( Amarogentin, a secoiridoid glycoside, abrogates platelet activation through PLC γ 2-PKC and MAPK pathways.
Chiu, HC; Lee, TY; Lien, LM; Lin, KH; Lu, WJ; Sheu, JR; Thomas, PA; Yen, TL, 2014
)
2.57

Pharmacokinetics

ExcerptReferenceRelevance
" The quantitation method was successfully applied to generate pharmacokinetic (PK) profile of markers as well as to detect other components in plasma after intravenous dose administration of herbal preparation in male Sprague-Dawley (SD) rats."( Simultaneous estimation of mangiferin and four secoiridoid glycosides in rat plasma using liquid chromatography tandem mass spectrometry and its application to pharmacokinetic study of herbal preparation.
Asthana, RK; Gupta, RC; Suryawanshi, S, 2007
)
0.34

Compound-Compound Interactions

ExcerptReferenceRelevance
" Induction of apoptosis was also higher after treatment with EGCG in combination with eugenol-amrogentin than individual compound treatments."( Epigallocatechin gallate in combination with eugenol or amarogentin shows synergistic chemotherapeutic potential in cervical cancer cell line.
Kumar Panda, C; Mandal, S; Pal, D; Roy, R; Sur, S, 2018
)
0.73

Bioavailability

ExcerptReferenceRelevance
" Information regarding the chemistry of amarogentin, its biological sources, bioavailability as a pharmacological agent for the treatment and management of skin disorders and various forms of cancers will be beneficial to the scientists in the medicinal field."( Amarogentin as Topical Anticancer and Anti-Infective Potential: Scope of Lipid Based Vesicular in its Effective Delivery.
Kumar, V; Patel, DK; Patel, K; Rahman, M; Verma, A, 2019
)
2.22
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 5.99.1.2 (DNA topoisomerase) inhibitorA topoisomerase inhibitor that inhibits the bacterial enzymes of the DNA topoisomerases, Type I class (EC 5.99.1.2) that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
secoiridoid glycosideA glycoside of any secoiridoid.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (4.55)18.2507
2000's7 (15.91)29.6817
2010's24 (54.55)24.3611
2020's11 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.04 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index5.32 (4.65)
Search Engine Demand Index51.72 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other44 (97.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]